Article Sidebar

PDF (Tiếng Việt)
Published: 2023-01-30
Abstract Views: 207
Views PDF (Tiếng Việt): 283
DOI: https://doi.org/10.52852/tcncyh.v160i12V2.1290
Issue
Vol. 160 No. 12V2 (2022)
Section
Các bài báo
How to Cite
Kiên, Đỗ H. ., & Tài, N. V. . (2023). 15. Factors associated with survival in patients with staged-III non-small cell lung cancer after concurrent chemoradiation as etoposide/cisplatin regimen and intensity modulated radiation therapy. Journal of Medical Research, 160(12V2), 120-127. https://doi.org/10.52852/tcncyh.v160i12V2.1290

15. Factors associated with survival in patients with staged-III non-small cell lung cancer after concurrent chemoradiation as etoposide/cisplatin regimen and intensity modulated radiation therapy

Do Hung Kien, Nguyen Van Tai

Main Article Content

Abstract

This is a retrospective, descriptive study aimed to assess the progression-free survival in non-small cell lung cancer patients treated with concurrent chemoradiation therapy as etoposide/cisplatin chemotherapy and intensity modulated radiation therapy and explore the factors associated with survival. The study is conducted with 37 patients diagnosed with staged-III non-small cell lung cancer patients at National Cancer Hospital from Jan 2018 to Jun 2022. The average progression-free survival (PFS) was 13.7 ± 1.4 months and the median progression-free survival was 14 ± 3.8 months. The 6-month and 12-month PFS was 81.1% and 54.7%, respectively. The average PFS for patients presented with ECOG 0 point and ECOG 1 point were 16.7 months and 10.2 month, respectively, and there was a significant difference between these groups (p = 0.03). Therefore, concurrent chemoradiation therapy as etoposide/cisplatin chemotherapy and intensity modulated radiation therapy can significantly increased survival time for stage III non-small cell lung cancer.

Article Details

Keywords

non-small cell lung cancer, stage III, etoposide/cisplatin, intensity modulated radiation therapy

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
2. Cordeiro de Lima VC, Baldotto CS, Barrios CH, et al. Stage III non–small-cell lung cancer treated with concurrent chemoradiation followed or not by consolidation chemotherapy: A survival analysis from a brazilian multicentric cohort. JGO. 2018;(4):1-11.
3. Curran W, Scott C, Langer C. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresectable stage III NSCLC: RTOG 9410. J Clin Oncol. 2003;22.
4. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692-2699.
5. Liang J, Bi N, Wu S, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Annals of Oncology. 2017;28(4):777-783.
6. Hàng Quốc Tuấn, và cs. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn III không mổ được bằng phác đồ hóa chất paclitaxel - cacboplatin kết hợp hóa xạ đồng thời. Tạp chí Ung thư học Việt Nam. 2020;4:68-75.
7. Lê Thị Yến. Đánh giá kết quả hóa xạ trị đồng thời phác đồ paclitaxel - carboplatin trong ung thư phổi không tế bào nhỏ giai đoạn IIIB tại Bệnh viện K. Luận án tiến sĩ y học, Trường Đại học Y Hà Nội; 2019.
8. Vũ Hữu Khiêm. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ băng phác đồ hóa - xạ trị với kĩ thuật PET/CT mô phỏng. Luận án tiến sĩ y học, Trường Đại học Y Hà Nội; 2018.
9. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-2190.